{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:02:57Z","timestamp":1779084177221,"version":"3.51.4"},"reference-count":96,"publisher":"MDPI AG","issue":"8","license":[{"start":{"date-parts":[[2023,7,26]],"date-time":"2023-07-26T00:00:00Z","timestamp":1690329600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Slovenian Research and Innovation Agency","award":["J3-4498"],"award-info":[{"award-number":["J3-4498"]}]},{"name":"Slovenian Research and Innovation Agency","award":["IRP-2021\/02-18"],"award-info":[{"award-number":["IRP-2021\/02-18"]}]},{"name":"University Medical Center Maribor","award":["J3-4498"],"award-info":[{"award-number":["J3-4498"]}]},{"name":"University Medical Center Maribor","award":["IRP-2021\/02-18"],"award-info":[{"award-number":["IRP-2021\/02-18"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Psoriasis is a chronic, immune-mediated and inflammatory skin disease. Although various biological drugs are available for psoriasis treatment, some patients have poor responses or do not respond to treatment. The aim of the present study was to highlight the molecular mechanism of responsiveness to current biological drugs for psoriasis treatment. To this end, we reviewed previously published articles that reported genes associated with treatment response to biological drugs in psoriasis, and gene ontology analysis was subsequently performed using the Cytoscape platform. Herein, we revealed a statistically significant association between NF-kappaB signaling (p value = 3.37 \u00d7 10\u22129), regulation of granulocyte macrophage colony-stimulating factor production (p value = 6.20 \u00d7 10\u22126), glial cell proliferation (p value = 2.41 \u00d7 10\u22125) and treatment response in psoriatic patients. To the best of our knowledge, we are the first to directly associate glial cells with treatment response. Taken together, our study revealed gene ontology (GO) terms, some of which were previously shown to be implicated in the molecular pathway of psoriasis, as novel GO terms involved in responsiveness in psoriatic disease patients.<\/jats:p>","DOI":"10.3390\/pharmaceutics15082024","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T01:50:37Z","timestamp":1690422637000},"page":"2024","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Gene Ontology Analysis Highlights Biological Processes Influencing Responsiveness to Biological Therapy in Psoriasis"],"prefix":"10.3390","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7921-6565","authenticated-orcid":false,"given":"Martina","family":"Kru\u0161i\u010d","sequence":"first","affiliation":[{"name":"Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1110-5345","authenticated-orcid":false,"given":"Gregor","family":"Jezernik","sequence":"additional","affiliation":[{"name":"Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1624-9428","authenticated-orcid":false,"given":"Uro\u0161","family":"Poto\u010dnik","sequence":"additional","affiliation":[{"name":"Center for Human Molecular Genetics and Pharmacogenomics, Faculty of Medicine, University of Maribor, Taborska ulica 8, 2000 Maribor, Slovenia"},{"name":"Faculty of Chemistry and Chemical Engineering, University of Maribor, Smetanova ulica 17, 2000 Maribor, Slovenia"},{"name":"Department for Science and Research, University Clinical Centre Maribor, Ljubljanska ulica 5, 2000 Maribor, Slovenia"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2023,7,26]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","unstructured":"Rendon, A., and Schakel, K. (2019). Psoriasis Pathogenesis and Treatment. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20061475"},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"m1590","DOI":"10.1136\/bmj.m1590","article-title":"National, regional, and worldwide epidemiology of psoriasis: Systematic analysis and modelling study","volume":"369","author":"Parisi","year":"2020","journal-title":"BMJ"},{"key":"ref_3","unstructured":"WHO (2016). Global Report on Psoriasis, WHO."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1016\/S0140-6736(20)32549-6","article-title":"Psoriasis","volume":"397","author":"Griffiths","year":"2021","journal-title":"Lancet"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"6916","DOI":"10.1038\/ncomms7916","article-title":"Genome-wide meta-analysis identifies multiple novel associations and ethnic heterogeneity of psoriasis susceptibility","volume":"6","author":"Yin","year":"2015","journal-title":"Nat. Commun."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"15382","DOI":"10.1038\/ncomms15382","article-title":"Large scale meta-analysis characterizes genetic architecture for common psoriasis associated variants","volume":"8","author":"Tsoi","year":"2017","journal-title":"Nat. Commun."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"611","DOI":"10.2147\/CCID.S227896","article-title":"Omics-Driven Biomarkers of Psoriasis: Recent Insights, Current Challenges, and Future Prospects","volume":"13","author":"Aydin","year":"2020","journal-title":"Clin. Cosmet. Investig. Dermatol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1080\/09546630701364768","article-title":"Psoriasis comorbidities","volume":"19","author":"Gottlieb","year":"2008","journal-title":"J. Dermatol. Treat."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1136\/jmg.2007.053595","article-title":"Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease","volume":"45","author":"Wolf","year":"2008","journal-title":"J. Med. Genet."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1945","DOI":"10.1001\/jama.2020.4006","article-title":"Pathophysiology, Clinical Presentation, and Treatment of Psoriasis: A Review","volume":"323","author":"Armstrong","year":"2020","journal-title":"JAMA"},{"key":"ref_11","first-page":"39","article-title":"Biologic Treatments of Psoriasis: An Update for the Clinician","volume":"15","author":"Brownstone","year":"2021","journal-title":"Biologics"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1056\/NEJMoa1314258","article-title":"Secukinumab in plaque psoriasis\u2014Results of two phase 3 trials","volume":"371","author":"Langley","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1007\/s13555-016-0102-0","article-title":"Ixekizumab for the Treatment of Psoriasis: A Review of Phase III Trials","volume":"6","author":"Farahnik","year":"2016","journal-title":"Dermatol. Ther."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1358\/dot.2017.53.5.2613690","article-title":"Brodalumab: The first anti-IL-17 receptor agent for psoriasis","volume":"53","author":"Puig","year":"2017","journal-title":"Drugs Today"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1016\/j.jaad.2019.11.040","article-title":"Maintenance of clinical response and consistent safety profile with up to 3 years of continuous treatment with guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials","volume":"82","author":"Reich","year":"2020","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"953","DOI":"10.5114\/ada.2022.120886","article-title":"Efficacy of guselkumab compared with adalimumab for psoriasis: A meta-analysis of randomized controlled studies","volume":"39","author":"Fu","year":"2022","journal-title":"Postepy Dermatol. Alergol."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.jaad.2007.09.010","article-title":"Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial","volume":"58","author":"Menter","year":"2008","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"712313","DOI":"10.3389\/fmed.2022.712313","article-title":"Novel Therapeutic Target(s) for Psoriatic Disease","volume":"9","author":"Thakur","year":"2022","journal-title":"Front. Med."},{"key":"ref_19","doi-asserted-by":"crossref","unstructured":"Wang, C.Y., Wang, C.W., Chen, C.B., Chen, W.T., Chang, Y.C., Hui, R.C., and Chung, W.H. (2023). Pharmacogenomics on the Treatment Response in Patients with Psoriasis: An Updated Review. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24087329"},{"key":"ref_20","doi-asserted-by":"crossref","unstructured":"Caputo, V., Strafella, C., Cosio, T., Lanna, C., Campione, E., Novelli, G., Giardina, E., and Cascella, R. (2021). Pharmacogenomics: An Update on Biologics and Small-Molecule Drugs in the Treatment of Psoriasis. Genes, 12.","DOI":"10.3390\/genes12091398"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.2217\/pgs.13.163","article-title":"Pharmacogenetics of topical and systemic treatment of psoriasis","volume":"14","author":"Cabaleiro","year":"2013","journal-title":"Pharmacogenomics"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Jezernik, G., Gorenjak, M., and Potocnik, U. (2022). Gene Ontology Analysis Highlights Biological Processes Influencing Non-Response to Anti-TNF Therapy in Rheumatoid Arthritis. Biomedicines, 10.","DOI":"10.3390\/biomedicines10081808"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1101\/gr.1239303","article-title":"Cytoscape: A software environment for integrated models of biomolecular interaction networks","volume":"13","author":"Shannon","year":"2003","journal-title":"Genome Res."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1093\/bioinformatics\/btp101","article-title":"ClueGO: A Cytoscape plug-in to decipher functionally grouped gene ontology and pathway annotation networks","volume":"25","author":"Bindea","year":"2009","journal-title":"Bioinformatics"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"W191","DOI":"10.1093\/nar\/gkz369","article-title":"g:Profiler: A web server for functional enrichment analysis and conversions of gene lists (2019 update)","volume":"47","author":"Raudvere","year":"2019","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1111\/exd.14215","article-title":"Genome-wide association analysis of psoriasis patients treated with anti-TNF drugs","volume":"29","author":"Sabador","year":"2020","journal-title":"Exp. Dermatol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.jdermsci.2020.05.011","article-title":"Specific single nucleotide polymorphism genotypes and association of an IL-12B polymorphism with secondary failure of infliximab therapy in Japanese psoriasis patients","volume":"99","author":"Torii","year":"2020","journal-title":"J. Dermatol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1007\/s40291-019-00409-x","article-title":"NFKBIZ and CW6 in Adalimumab Response Among Psoriasis Patients: Genetic Association and Alternative Transcript Analysis","volume":"23","author":"Batalla","year":"2019","journal-title":"Mol. Diagn. Ther."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2120","DOI":"10.1016\/j.jaci.2018.11.038","article-title":"HLA-C*06:02 genotype is a predictive biomarker of biologic treatment response in psoriasis","volume":"143","author":"Dand","year":"2019","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"7","DOI":"10.2217\/pgs-2017-0143","article-title":"Polymorphisms associated with adalimumab and infliximab response in moderate-to-severe plaque psoriasis","volume":"19","author":"Reolid","year":"2018","journal-title":"Pharmacogenomics"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1684\/ejd.2017.3071","article-title":"Psoriasis pharmacogenetics: HLA-Cw*0602 as a marker of therapeutic response to ustekinumab","volume":"27","author":"Raposo","year":"2017","journal-title":"Eur. J. Dermatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/tpj.2017.31","article-title":"Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis","volume":"18","author":"Loft","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"631","DOI":"10.2217\/pgs-2017-0014","article-title":"Polymorphisms associated with etanercept response in moderate-to-severe plaque psoriasis","volume":"18","author":"Belmonte","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/bjd.15387","article-title":"Role of the HLA-C*06 allele in clinical response to ustekinumab: Evidence from real life in a large cohort of European patients","volume":"177","author":"Talamonti","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"157","DOI":"10.2217\/pgs-2016-0122","article-title":"Pharmacogenetics of ustekinumab in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Cabaleiro","year":"2017","journal-title":"Pharmacogenomics"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1111\/1346-8138.13412","article-title":"Genetic prediction of the effectiveness of biologics for psoriasis treatment","volume":"43","author":"Nishikawa","year":"2016","journal-title":"J. Dermatol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/tpj.2016.64","article-title":"New polymorphisms associated with response to anti-TNF drugs in patients with moderate-to-severe plaque psoriasis","volume":"18","author":"Cabaleiro","year":"2018","journal-title":"Pharmacogenomics J."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"1288","DOI":"10.1111\/bjd.15005","article-title":"Polymorphisms in CD84, IL12B and TNFAIP3 are associated with response to biologics in patients with psoriasis","volume":"176","author":"Coenen","year":"2017","journal-title":"Br. J. Dermatol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/tpj.2016.16","article-title":"FCGR3A-V158F polymorphism is a disease-specific pharmacogenetic marker for the treatment of psoriasis with Fc-containing TNFalpha inhibitors","volume":"17","author":"Mendrinou","year":"2017","journal-title":"Pharmacogenomics J."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s40291-016-0198-z","article-title":"A Pharmacogenetic Study of Psoriasis Risk Variants in a Greek Population and Prediction of Responses to Anti-TNF-alpha and Anti-IL-12\/23 Agents","volume":"20","author":"Masouri","year":"2016","journal-title":"Mol. Diagn. Ther."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1159\/000441719","article-title":"IL12B (p40) Gene Polymorphisms Contribute to Ustekinumab Response Prediction in Psoriasis","volume":"232","author":"Galluzzo","year":"2016","journal-title":"Dermatology"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.2217\/pgs.15.107","article-title":"The polymorphism rs763780 in the IL-17F gene is associated with response to biological drugs in patients with psoriasis","volume":"16","author":"Cabaleiro","year":"2015","journal-title":"Pharmacogenomics"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s00403-014-1533-z","article-title":"The TNFRSF1B rs1061622 polymorphism (p.M196R) is associated with biological drug outcome in Psoriasis patients","volume":"307","author":"Batalla","year":"2015","journal-title":"Arch. Dermatol. Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/tpj.2014.71","article-title":"Association of the PDE3A-SLCO1C1 locus with the response to anti-TNF agents in psoriasis","volume":"15","author":"Julia","year":"2015","journal-title":"Pharmacogenomics J."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1111\/bjd.13056","article-title":"Human leucocyte antigen-Cw6 as a predictor for clinical response to ustekinumab, an interleukin-12\/23 blocker, in Chinese patients with psoriasis: A retrospective analysis","volume":"171","author":"Chiu","year":"2014","journal-title":"Br. J. Dermatol."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1111\/bjd.12425","article-title":"The relationship between tumour necrosis factor (TNF)-alpha promoter and IL12B\/IL-23R genes polymorphisms and the efficacy of anti-TNF-alpha therapy in psoriasis: A case-control study","volume":"169","author":"Gallo","year":"2013","journal-title":"Br. J. Dermatol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"3777","DOI":"10.3748\/wjg.v22.i14.3777","article-title":"Multi-locus genetic risk score predicts risk for Crohn\u2019s disease in Slovenian population","volume":"22","author":"Zupancic","year":"2016","journal-title":"World J. Gastroenterol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1055\/a-0981-6516","article-title":"Genetic prediction profile for adalimumab response in Slovenian Crohn\u2019s disease patients","volume":"57","author":"Gorenjak","year":"2019","journal-title":"Z. Gastroenterol."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"1612","DOI":"10.1136\/gut.2009.178665","article-title":"Mucosal gene signatures to predict response to infliximab in patients with ulcerative colitis","volume":"58","author":"Arijs","year":"2009","journal-title":"Gut"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00016.2018","article-title":"The multiple faces of inflammatory enteric glial cells: Is Crohn\u2019s disease a gliopathy?","volume":"315","author":"Pochard","year":"2018","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/jir.2021.0116","article-title":"The Involvement of Glial Cell-Derived Neurotrophic Factor in Inflammatory Bowel Disease","volume":"42","author":"Chen","year":"2022","journal-title":"J. Interferon Cytokine Res."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.it.2021.01.005","article-title":"Diversity and Function of Glial Cell Types in Multiple Sclerosis","volume":"42","author":"Schirmer","year":"2021","journal-title":"Trends Immunol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41582-022-00624-x","article-title":"The role of glial cells in multiple sclerosis disease progression","volume":"18","author":"Healy","year":"2022","journal-title":"Nat. Rev. Neurol."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1111\/cns.13144","article-title":"Secukinumab attenuates reactive astrogliosis via IL-17RA\/(C\/EBPbeta)\/SIRT1 pathway in a rat model of germinal matrix hemorrhage","volume":"25","author":"Liu","year":"2019","journal-title":"CNS Neurosci. Ther."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1111\/j.1468-3083.2008.02591.x","article-title":"Patients\u2019 perspective of pruritus in chronic plaque psoriasis: A questionnaire-based study","volume":"22","author":"Amatya","year":"2008","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1046\/j.1365-2133.2000.03829.x","article-title":"The prevalence and clinical characteristics of pruritus among patients with extensive psoriasis","volume":"143","author":"Yosipovitch","year":"2000","journal-title":"Br. J. Dermatol."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"e00754","DOI":"10.1002\/prp2.754","article-title":"Spinal glial cells in itch modulation","volume":"9","author":"Tsuda","year":"2021","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1016\/S0140-6736(15)60125-8","article-title":"Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): Results from two phase 3 randomised trials","volume":"386","author":"Griffiths","year":"2015","journal-title":"Lancet"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1111\/ijd.13236","article-title":"Secukinumab improves patient-reported psoriasis symptoms of itching, pain, and scaling: Results of two phase 3, randomized, placebo-controlled clinical trials","volume":"55","author":"Strober","year":"2016","journal-title":"Int. J. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"820","DOI":"10.2340\/00015555-3195","article-title":"Secukinumab Provides Rapid Relief From Itching and Pain in Patients with Moderate-to-Severe Psoriasis: Patient Symptom Diary Data from Two Phase 3, Randomized, Placebo-controlled Clinical Trials","volume":"99","author":"Yosipovitch","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.jaad.2016.08.008","article-title":"Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study","volume":"76","author":"Blauvelt","year":"2017","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1111\/jdv.14913","article-title":"Improvement in itch and other psoriasis symptoms with brodalumab in phase 3 randomized controlled trials","volume":"32","author":"Gottlieb","year":"2018","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1016\/j.jaad.2016.07.040","article-title":"Tofacitinib improves pruritus and health-related quality of life up to 52 weeks: Results from 2 randomized phase III trials in patients with moderate to severe plaque psoriasis","volume":"75","author":"Feldman","year":"2016","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"298","DOI":"10.2340\/00015555-3086","article-title":"Antipruritic Effects of Janus Kinase Inhibitor Tofacitinib in a Mouse Model of Psoriasis","volume":"99","author":"Hashimoto","year":"2019","journal-title":"Acta Derm. Venereol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1744806920934998","DOI":"10.1177\/1744806920934998","article-title":"Microglia-mediated chronic psoriatic itch induced by imiquimod","volume":"16","author":"Xu","year":"2020","journal-title":"Mol. Pain"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1373\/clinchem.2006.075614","article-title":"Lipocalin-2 is an inflammatory marker closely associated with obesity, insulin resistance, and hyperglycemia in humans","volume":"53","author":"Wang","year":"2007","journal-title":"Clin. Chem."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"4065","DOI":"10.1172\/JCI42004","article-title":"Lipocalin 2 is essential for chronic kidney disease progression in mice and humans","volume":"120","author":"Viau","year":"2010","journal-title":"J. Clin. Investig."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1002\/jlb.66.6.989","article-title":"The individual regulation of granule protein mRNA levels during neutrophil maturation explains the heterogeneity of neutrophil granules","volume":"66","author":"Cowland","year":"1999","journal-title":"J. Leukoc. Biol."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1530\/EJE-07-0633","article-title":"Implication of lipocalin-2 and visfatin levels in patients with coronary heart disease","volume":"158","author":"Choi","year":"2008","journal-title":"Eur. J. Endocrinol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1093\/eurheartj\/ehp088","article-title":"Increased systemic and myocardial expression of neutrophil gelatinase-associated lipocalin in clinical and experimental heart failure","volume":"30","author":"Yndestad","year":"2009","journal-title":"Eur. Heart J."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"8171373","DOI":"10.1155\/2019\/8171373","article-title":"Relationship between the Degrees of Itch and Serum Lipocalin-2 Levels in Patients with Psoriasis","volume":"2019","author":"Aizawa","year":"2019","journal-title":"J. Immunol. Res."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"296","DOI":"10.1111\/j.1365-2230.2011.04265.x","article-title":"Serum lipocalin-2 levels are increased in patients with psoriasis","volume":"37","author":"Kamata","year":"2012","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1016\/j.jid.2016.03.002","article-title":"Increased Lipocalin-2 Contributes to the Pathogenesis of Psoriasis by Modulating Neutrophil Chemotaxis and Cytokine Secretion","volume":"136","author":"Shao","year":"2016","journal-title":"J. Investig. Dermatol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1182\/blood.V83.3.799.799","article-title":"Identification of neutrophil gelatinase-associated lipocalin as a novel matrix protein of specific granules in human neutrophils","volume":"83","author":"Kjeldsen","year":"1994","journal-title":"Blood"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1161\/STROKEAHA.114.005733","article-title":"Neuronal production of lipocalin-2 as a help-me signal for glial activation","volume":"45","author":"Xing","year":"2014","journal-title":"Stroke"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1523\/JNEUROSCI.5273-08.2009","article-title":"Lipocalin-2 is an autocrine mediator of reactive astrocytosis","volume":"29","author":"Lee","year":"2009","journal-title":"J. Neurosci."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"497","DOI":"10.2340\/00015555-1265","article-title":"Visual analogue scale: Evaluation of the instrument for the assessment of pruritus","volume":"92","author":"Reich","year":"2012","journal-title":"Acta Derm. Venereol."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.jdermsci.2012.11.002","article-title":"NF-kappaB: An essential transcription factor in psoriasis","volume":"69","author":"Goldminz","year":"2013","journal-title":"J. Dermatol. Sci."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.3389\/fimmu.2019.02342","article-title":"Targeting the Janus Kinase Family in Autoimmune Skin Diseases","volume":"10","author":"Howell","year":"2019","journal-title":"Front. Immunol."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1038\/nm1201-1291","article-title":"Possible new role for NF-kappaB in the resolution of inflammation","volume":"7","author":"Lawrence","year":"2001","journal-title":"Nat. Med."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1038\/s41467-021-25066-9","article-title":"Enhanced NF-kappaB signaling in type-2 dendritic cells at baseline predicts non-response to adalimumab in psoriasis","volume":"12","author":"Ale","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1159\/000247852","article-title":"Granulocyte-macrophage colony-stimulating factor in psoriasis","volume":"181","author":"Takematsu","year":"1990","journal-title":"Dermatologica"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1111\/j.1365-2230.1994.tb02687.x","article-title":"Correlated increases of tumour necrosis factor-alpha, interleukin-6 and granulocyte monocyte-colony stimulating factor levels in suction blister fluids and sera of psoriatic patients relationships with disease severity","volume":"19","author":"Bonifati","year":"1994","journal-title":"Clin. Exp. Dermatol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1111\/1523-1747.ep12464470","article-title":"Keratinocyte derived T-cell growth factor (KTGF) is identical to granulocyte macrophage colony stimulating factor (GM-CSF)","volume":"91","author":"Kupper","year":"1988","journal-title":"J. Investig. Dermatol."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1038\/nrrheum.2015.161","article-title":"Targeting GM-CSF in inflammatory diseases","volume":"12","author":"Wicks","year":"2016","journal-title":"Nat. Rev. Rheumatol."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1189\/jlb.0212101","article-title":"Targeting the Th17 pathway in psoriasis","volume":"92","author":"Elloso","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.4049\/jimmunol.169.6.2875","article-title":"Endogenous granulocyte-macrophage colony-stimulating factor overexpression in vivo results in the long-term recruitment of a distinct dendritic cell population with enhanced immunostimulatory function","volume":"169","author":"Miller","year":"2002","journal-title":"J. Immunol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1111\/bjd.17195","article-title":"Granulocyte-macrophage colony-stimulating factor (GM-CSF) as a therapeutic target in psoriasis: Randomized, controlled investigation using namilumab, a specific human anti-GM-CSF monoclonal antibody","volume":"180","author":"Papp","year":"2019","journal-title":"Br. J. Dermatol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"e12725","DOI":"10.1111\/sji.12725","article-title":"Serum cytokine measurements and biological therapy of psoriasis\u2014Prospects for personalized treatment?","volume":"88","author":"Solberg","year":"2018","journal-title":"Scand. J. Immunol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1038\/ng.604","article-title":"Genome-wide meta-analyses identifies seven loci associated with platelet aggregation in response to agonists","volume":"42","author":"Johnson","year":"2010","journal-title":"Nat. Genet."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"154157","DOI":"10.1016\/j.cyto.2017.09.013","article-title":"Platelet-derived chemokines in inflammation and atherosclerosis","volume":"122","author":"Bakogiannis","year":"2019","journal-title":"Cytokine"},{"key":"ref_92","first-page":"97","article-title":"Current Developments in the Immunology of Psoriasis","volume":"93","author":"Gran","year":"2020","journal-title":"Yale J. Biol. Med."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1111\/j.1365-2133.2010.09662.x","article-title":"Interleukin-1 from epithelial cells fosters T cell-dependent skin inflammation","volume":"162","author":"Renne","year":"2010","journal-title":"Br. J. Dermatol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.1038\/ncomms4986","article-title":"Differential developmental requirement and peripheral regulation for dermal Vgamma4 and Vgamma6T17 cells in health and inflammation","volume":"5","author":"Cai","year":"2014","journal-title":"Nat. Commun."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"865875","DOI":"10.3389\/fimmu.2022.865875","article-title":"Based on Gene Expression Analysis: Low-Density Neutrophil Expression Is a Characteristic of the Fast Responders Treated with Guselkumab for Psoriasis","volume":"13","author":"Lu","year":"2022","journal-title":"Front. Immunol."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1007\/s10787-018-0530-9","article-title":"IL-1beta, IL-17A and combined phototherapy predicts higher while previous systemic biologic treatment predicts lower treatment response to etanercept in psoriasis patients","volume":"27","author":"Liu","year":"2019","journal-title":"Inflammopharmacology"}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/8\/2024\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T20:19:29Z","timestamp":1760127569000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/15\/8\/2024"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,26]]},"references-count":96,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2023,8]]}},"alternative-id":["pharmaceutics15082024"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics15082024","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,26]]}}}